Trovagene Inc., of San Diego, reported summary data from a phase I study conducted by Nerviano Medical Sciences Inc., of Nerviano, Italy, with PCM-075, a polo-like kinase inhibitor, with thrombocytopenia and neutropenia identified as the primary dose-limiting toxicities, which the company described as consistent with the expected mechanism of action and results from preclinical studies. Read More
Pharmamar SA, of Madrid, Spain, said it inked a licensing deal with Eczacıbaşı Group, of Istanbul, to commercialize marine-derived cancer drug Aplidin (plitidepsin) in Turkey. Read More
Antibe Therapeutics Inc., of Toronto, filed for a best efforts offering intended to raise between $3 million and $5 million. The proposed offering will consist of yet-to-be-priced units of the company comprising one common share and one-half of one common share purchase warrant. Read More
The latest FDA commissioner may be in an uncomfortable place where the Trump administration's budget proposal is concerned, but Scott Gottlieb told a congressional committee that the agency will undertake several actions to bolster competition in the drug marketplace, including the publication of a list of off-patent drugs that are not represented by a generic. Read More
SHANGHAI – The hot topic at the 9th DIA China annual meeting was China's proposed entry into the ICH, a global body that facilitates the harmonizing of drug regulations across countries. Read More
DUBLIN – Harpoon Therapeutics Inc. has landed a $45 million series B round to enable it to further develop its distinctive approach to the discovery of post-antibody scaffolds with multiple specificities. Read More
With an FDA advisory committee voting 14-1 Thursday to recommend licensure of Hospira Inc.'s epoetin biosimilar, the U.S. is one step closer to catching up with other markets that are nearly a decade ahead on the biosimilar path. Read More
